AP
APT
—
NYSE
Diversified Medical Equipment & Supplies
Alpha Pro Tech Ltd
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
50,9M USD
P/E
19,0x
EV / Rev
—
Div yield
—
Op margin
—
ROE
1,1 %
Net margin
—
Debt / equity
—
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$6,05
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
Alpha Pro Tech Ltd designs, develops, and markets performance-based products for the construction, industrial, and protective apparel markets, including housewrap, synthetic roof underlayment, and N-95 respirators.
Business. ALPHA PRO TECH LTD (APT) is a medical devices company operating within the Healthcare Equipment & Supplies sector. The firm generates revenue through the sale of products and is headquartered in the United States. It is primarily listed on the New York Stock Exchange under the ticker symbol APT. Specific details regarding operating segments and geographic revenue mix are not available.
Classification99 %
SectorHealth Care
Industry groupDiversified Medical Equipment & Supplies
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
At a glance
Score
—
not yet scored
Valuation→
19,0x
P/E
Analysts
—
not yet wired
Ownership→
Arrowstreet Capital, Limited Partnership
largest disclosed fund holder
Profitability→
1,1 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to APT. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
ALPHA PRO TECH LTD (APT) is a medical devices company operating within the Healthcare Equipment & Supplies sector. The firm generates revenue through the sale of products and is headquartered in the United States. It is primarily listed on the New York Stock Exchange under the ticker symbol APT. Specific details regarding operating segments and geographic revenue mix are not available.
Classification99 %
SectorHealth Care
Industry groupDiversified Medical Equipment & Supplies
AI synthesis
GENERATEDAlpha Pro Tech Ltd maintains a strong liquidity position with $16.88 million in cash and equivalents, and a current ratio of 19.81, indicating significant short-term financial flexibility. The company's price-to-book ratio of 1.06 and price-to-tangible-book ratio of 1.06 suggest that the market values the company's equity in line with its tangible book value. The debt-to-equity ratio of 0.0 indicates no leverage, which reduces financial risk but may also limit growth opportunities.
The company's profitability metrics show a return on equity of 1.11% and a return on assets of 0.96%, which are below the industry median for medical equipment and supplies firms. This suggests that the company is not generating returns as efficiently as its peers. The gross profit of $5.52 million and operating income of $580,000 indicate that the company is profitable but faces challenges in converting revenue into net income.
Alpha Pro Tech's revenue is concentrated in a few key segments, with a significant portion derived from construction and industrial products. The company's exposure to the construction sector is notable, as it relies on demand for housewrap and synthetic roof underlayment. The company also has a product line for protective apparel, including N-95 respirators, which experience increased demand during public health crises.
The company's growth trajectory is influenced by its ability to bring new products to market and meet increased demand. Recent capital expenditures of $117,000 suggest ongoing investment in manufacturing capabilities. However, the company's free cash flow of -$105,000 indicates that it is currently spending more on operations than it is generating, which could impact its ability to fund future growth without external financing.
The company faces medium dilution risk, as indicated by the risk assessment, with potential sources including future offerings to meet increased product demand. The company has also mentioned the possibility of stockpiling inventory during periods of high demand, which could lead to increased working capital requirements and potential markdowns if demand does not materialize.
Recent events include the company's decision not to impair its investment in Harmony as of March 31, 2026, and December 31, 2025. The company is also expanding its manufacturing capacity in Valdosta, Georgia, and through its joint venture in India to support new product offerings. These developments suggest a strategic focus on scaling production to meet anticipated demand for its products.
Key takeaways
- Alpha Pro Tech Ltd has a strong liquidity position with a current ratio of 19.81 and $16.88 million in cash and equivalents.
- The company's profitability metrics, including a return on equity of 1.11%, are below the industry median, indicating inefficiencies in converting revenue into net income.
- Revenue is concentrated in construction and industrial products, with a notable reliance on demand for housewrap and synthetic roof underlayment.
- The company is investing in manufacturing capabilities to meet increased product demand, but its free cash flow of -$105,000 suggests current operational spending exceeds cash generation.
- Medium dilution risk is present, with potential sources including future offerings to support growth initiatives.
- Recent strategic moves include expanding manufacturing in Valdosta, Georgia, and through a joint venture in India to support new product offerings.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Quarterly
Annual
QUARTERLYFiled 2026-03-31
Q4 2025 · Quarter highlights
Operating income $580.0k.
Revenue—
Operating income$580.0k
Net income$702.0k
Free cash flow-$105.0k
EPS—
Operating cash flow$12.0k
Financials
Income statement
Revenue—
Gross profit$5.5M
Operating income$580.0k
Net income$702.0k
Balance sheet
Total assets$73.0M
Total liabilities$10.0M
Total equity$63.0M
Cash & equivalents$16.9M
Long-term debt—
Cash flow
Operating cash flow$12.0k
CapEx$117.0k
Free cash flow-$105.0k
SBC$132.0k
Highlights
- ▍Operating income $580.0k
QUARTERLYFiled 2025-09-30
Q2 2025 · Quarter highlights
Operating income $2.9M.
Revenue—
Operating income$2.9M
Net income$2.8M
Free cash flow$1.7M
EPS—
Operating cash flow$2.1M
Financials
Income statement
Revenue—
Gross profit$17.4M
Operating income$2.9M
Net income$2.8M
Balance sheet
Total assets$73.9M
Total liabilities$11.3M
Total equity$62.5M
Cash & equivalents$17.7M
Long-term debt—
Cash flow
Operating cash flow$2.1M
CapEx$372.0k
Free cash flow$1.7M
SBC$408.0k
Highlights
- ▍Operating income $2.9M
QUARTERLYFiled 2025-06-30
Q1 2025 · Quarter highlights
Operating income $1.8M.
Revenue—
Operating income$1.8M
Net income$1.9M
Free cash flow-$2.1M
EPS—
Operating cash flow-$1.9M
Financials
Income statement
Revenue—
Gross profit$11.5M
Operating income$1.8M
Net income$1.9M
Balance sheet
Total assets$73.2M
Total liabilities$10.9M
Total equity$62.2M
Cash & equivalents$14.5M
Long-term debt—
Cash flow
Operating cash flow-$1.9M
CapEx$273.0k
Free cash flow-$2.1M
SBC$272.0k
Highlights
- ▍Operating income $1.8M
ANNUALFiled 2025-12-31
FY 2025 · Full-year highlights
Operating income $3.8M.
Revenue—
Operating income$3.8M
Net income$3.5M
Free cash flow$1.7M
EPS—
Operating cash flow$2.4M
Financials
Income statement
Revenue—
Gross profit$22.5M
Operating income$3.8M
Net income$3.5M
Balance sheet
Total assets$74.1M
Total liabilities$11.7M
Total equity$62.5M
Cash & equivalents$17.0M
Long-term debt—
Cash flow
Operating cash flow$2.4M
CapEx$639.0k
Free cash flow$1.7M
SBC$540.0k
Highlights
- ▍Operating income $3.8M
ANNUALFiled 2024-12-31
FY 2024 · Full-year highlights
Operating income $3.4M.
Revenue—
Operating income$3.4M
Net income$3.9M
Free cash flow$1.9M
EPS—
Operating cash flow$5.7M
Financials
Income statement
Revenue—
Gross profit$22.9M
Operating income$3.4M
Net income$3.9M
Balance sheet
Total assets$73.7M
Total liabilities$11.5M
Total equity$62.2M
Cash & equivalents$18.6M
Long-term debt—
Cash flow
Operating cash flow$5.7M
CapEx$3.8M
Free cash flow$1.9M
SBC$463.0k
Highlights
- ▍Operating income $3.4M
ANNUALFiled 2024-12-31
FY 2025 · Full-year highlights
Operating income $3.4M.
Revenue—
Operating income$3.4M
Net income$3.9M
Free cash flow$1.9M
EPS—
Operating cash flow$5.7M
Financials
Income statement
Revenue—
Gross profit$22.9M
Operating income$3.4M
Net income$3.9M
Balance sheet
Total assets$73.7M
Total liabilities$11.5M
Total equity$62.2M
Cash & equivalents$18.6M
Long-term debt—
Cash flow
Operating cash flow$5.7M
CapEx$3.8M
Free cash flow$1.9M
SBC$463.0k
Highlights
- ▍Operating income $3.4M
ANNUALFiled 2023-12-31
FY 2023 · Full-year highlights
Operating income $4.1M.
Revenue—
Operating income$4.1M
Net income$4.2M
Free cash flow$7.7M
EPS—
Operating cash flow$8.5M
Financials
Income statement
Revenue—
Gross profit$22.8M
Operating income$4.1M
Net income$4.2M
Balance sheet
Total assets$68.8M
Total liabilities$7.2M
Total equity$61.6M
Cash & equivalents$20.4M
Long-term debt—
Cash flow
Operating cash flow$8.5M
CapEx$792.0k
Free cash flow$7.7M
SBC$170.0k
Highlights
- ▍Operating income $4.1M
ANNUALFiled 2023-12-31
FY 2024 · Full-year highlights
Operating income $4.1M.
Revenue—
Operating income$4.1M
Net income$4.2M
Free cash flow$7.7M
EPS—
Operating cash flow$8.5M
Financials
Income statement
Revenue—
Gross profit$22.8M
Operating income$4.1M
Net income$4.2M
Balance sheet
Total assets$68.8M
Total liabilities$7.2M
Total equity$61.6M
Cash & equivalents$20.4M
Long-term debt—
Cash flow
Operating cash flow$8.5M
CapEx$792.0k
Free cash flow$7.7M
SBC$170.0k
Highlights
- ▍Operating income $4.1M
Valuation FY
Market price
$4,93
Market cap
$66.9M
Enterprise valueⓘ
$50.1M
P/Eⓘ
19.0x
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
13.0x
EV / OCFⓘ
4172.2x
P / Bⓘ
1.1x
P / Tangible bookⓘ
1.1x
Tangible book
$63.0M
Net cashⓘ
$16.9M
Current ratioⓘ
19.8
Debt / equityⓘ
—
ROAⓘ
1.0%
ROEⓘ
1.1%
Cash conversionⓘ
2.0%
CapEx / revenueⓘ
—
SBC / revenueⓘ
—
Dilution ratioⓘ
2.0%
Revenue by segment
Business relationships
Business relationships3 disclosed relationships · 1 type · extracted from filings & disclosures
Supply chain
Vendors → APT ↔ Partners → Customers · click any node to drill
3 mentions in 10-K0 from corporate websites0 from news dispatches
Updated 2026-07-04Peer comparison
Peer comparison8 peers · vs APT · multiples and returns
AB
ABT—
Abbott Laboratories
$107,13
187,2B USDP/E
26,3x
-69,1 vs self
Div yield
2,4 %
— vs self
ROE
12,5 %
+11,4 vs self
MD
MDT—
Medtronic PLC
$86,19
110,3B USDP/E
21,4x
-74,0 vs self
Div yield
3,4 %
— vs self
ROE
9,7 %
+8,6 vs self
MD
MDLN—
MEDLINE INC.
$40,47
53,2B USDP/E
202,6x
+107,2 vs self
Div yield
—
— vs self
ROE
—
— vs self
SY
SYK—
Stryker Corp
$341,20
131,8B USDP/E
38,0x
-57,4 vs self
Div yield
—
— vs self
ROE
13,5 %
+12,4 vs self
BD
BDX—
Becton Dickinson And Co
$170,21
48,4B USDP/E
25,6x
-69,8 vs self
Div yield
2,8 %
— vs self
ROE
7,0 %
+5,8 vs self
HS
HSIC—
Henry Schein Inc
$88,21
10,1B USDP/E
80,5x
-14,8 vs self
Div yield
—
— vs self
ROE
3,0 %
+1,9 vs self
BA
BAX—
Baxter International Inc
$28,10
14,5B USDP/E
—
— vs self
Div yield
2,3 %
— vs self
ROE
-15,4 %
-16,5 vs self
SO
SOLV—
SOLVENTUM CORPORATION
$76,83
13,3B USDP/E
8,6x
-86,8 vs self
Div yield
—
— vs self
ROE
30,8 %
+29,7 vs self
Market position
Stress test
— missing data
Predictor forecast
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
— missing data
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskMedium
Liquidity riskLow
Filing-based flags
- Source documents mention dilution or offering risk.
Benchmarks vs cohort
ROE1,1 %Above median
D/E0,00Above median
Cash Conv0,02Bottom quartile
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net disposed 6 360 sh3 exercises1 insiders
- Director · options → common stockDisposed 3 093 @ $4,23exercise · 2026-05-19
- Director · options → common stockDisposed 1 634 @ $3,99exercise · 2026-05-15
- Director · options → common stockDisposed 1 633 @ $3,99exercise · 2026-05-15
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Regulatory filings
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
Source documents
- ALPHA PRO TECH LTD company facts · 2026-05-27
- ALPHA PRO TECH LTD 10-Q 2026-05-07 · 2026-05-27
- ALPHA PRO TECH LTD 10-K 2026-03-11 · 2026-05-27
- ALPHA PRO TECH LTD 10-Q 2025-11-06 · 2026-05-27
- ALPHA PRO TECH LTD 10-Q 2025-08-07 · 2026-05-27
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2025-12-310,00 %$3M
- Investment Managers · as of 2024-06-300,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
Leadership
- Lloyd HoffmanPresident, Chief Executive Officer, Director
Insider activity
Net selling0 buys · 12 sellsnet -$317K6 insiders · last 365d
- Director · optionsOther 4 900 @ $3,99$20K · 2026-05-15
- Director · common stockSold 6 186 @ $5,56$34K · 2026-05-15
- Director · optionsOther 4 900 @ $4,23$21K · 2026-05-15
- Director · common stockSold 4 900 @ $5,88$29K · 2026-05-14
- Director · common stockSold 5 000 @ $6,33$32K · 2026-05-12
- Director · common stockSold 5 000 @ $6,28$31K · 2026-05-12
- Director · common stockSold 5 000 @ $6,04$30K · 2026-05-12
- Director · common stockSold 5 000 @ $6,35$32K · 2026-05-12
- Director · common stockSold 3 886 @ $7,03$27K · 2026-05-11
- Director · Common StockSold 2 260 @ $4,94$11K · 2026-03-17
- Director · Common StockSold 4 740 @ $4,84$23K · 2026-03-16
- Director, CEO AND PRESIDENT · Common stockOther 12 425 · 2026-01-05
- Director · Common StockSold 4 740 @ $4,61$22K · 2025-12-05
- Director · Common StockOther 5 615 · 2025-09-29
- Director · Common StockOther 5 615 · 2025-09-29
- Director · common stockOther 5 615 · 2025-09-29
- Director · common stockOther 4 740 · 2025-09-29
- Director · Common StockSold 6 400 @ $4,88$31K · 2025-09-09
- Director · Common StockSold 3 013 @ $4,81$14K · 2025-09-09
Short positioning
48.9Kshares short-34.8% vs prior
1days to cover
53.5%short of daily vol
2.6Kfails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
APTCanonical
NYSE · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskMedium
Liquidity riskLow
Source documents mention dilution or offering risk.
Relationship graph
This companySectorCustomers
Evidence & claims
From filings & derived data- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -2.9%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -5.7%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -58.4%Derived (calculated)
- Gross profit (YoY) (2025-12-31 vs 2024-12-31): -1.7%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 0.5%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): -10.3%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 11.3%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 1.3%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 0.4%Derived (calculated)
- Return on assets (FY 2025-12-31): 4.7%Derived (calculated)
- Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 4.9%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -8.8%Derived (calculated)
- Current ratio (FY 2025-12-31): 12.94xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.19xDerived (calculated)
- Return on equity (FY 2025-12-31): 5.6%Derived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): -83.2%Derived (calculated)
- Current assets (annual): USD 52.52MSEC XBRL filing
- Total assets (annual): USD 74.13MSEC XBRL filing
- Current liabilities (annual): USD 4.06MSEC XBRL filing
- Total liabilities (annual): USD 11.65MSEC XBRL filing
- Gross profit (annual): USD 22.54MSEC XBRL filing
- EPS (diluted) (annual): USD-PER-SHARES 0SEC XBRL filing
- EPS (basic) (annual): USD-PER-SHARES 0SEC XBRL filing
- Operating income (annual): USD 3.84MSEC XBRL filing
Showing 24 of 60 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-05-19 00:00 UTCINSIDER12 insider transactions — 2026-05 · net sell $175k 3 derivative
2026-05-19 00:00 UTCINSIDER12 insider transactions — 2026-05 · net sell $175k 3 derivative
2026-05-19INSIDERGarcia David R disposed of 3.1k sh options — Director
2026-05-15INSIDERGarcia David R transacted 4.9k sh options — Director ~$20k
2026-05-15INSIDERGarcia David R sold 6.2k sh — Director ~$34k
2026-05-15INSIDERGarcia David R disposed of 1.6k sh options — Director
2026-05-15INSIDERGarcia David R disposed of 1.6k sh options — Director
2026-05-14INSIDERGarcia David R sold 4.9k sh — Director ~$29k
2026-05-12INSIDERMONTGOMERY CHARLES D sold 5.0k sh — Director ~$30k
2026-05-11INSIDERMONTGOMERY CHARLES D sold 3.9k sh — Director ~$27k
2026-03-31EARNINGSQuarterly results — Q4 2025 Net USD 0.7M
2026-03-17 00:00 UTCINSIDER2 insider transactions — 2026-03
2026-03-17 00:00 UTCINSIDER2 insider transactions — 2026-03
2026-03-17INSIDERRITOTA JOHN sold 2.3k sh — Director ~$11k
2026-03-16INSIDERRITOTA JOHN sold 4.7k sh — Director ~$23k
2026-01-05 00:00 UTCINSIDER1 insider transaction — 2026-01
2026-01-05 00:00 UTCINSIDER1 insider transaction — 2026-01
2026-01-05INSIDERHOFFMAN LLOYD transacted 12.4k sh — Director, CEO AND PRESIDENT
2025-12-31EARNINGSQuarterly results — Q3 2025
2025-12-31EARNINGSAnnual results — FY 2025 Net USD 3.5M
2025-12-05 00:00 UTCINSIDER1 insider transaction — 2025-12
2025-12-05 00:00 UTCINSIDER1 insider transaction — 2025-12
2025-12-05INSIDERBuchan James sold 4.7k sh — Director ~$22k
2025-09-30EARNINGSQuarterly results — Q2 2025 Net USD 2.8M
2025-09-29INSIDERGarcia David R transacted 5.6k sh — Director
2025-09-29INSIDERShaw Benjamin A transacted 4.7k sh — Director
2025-09-29INSIDERBuchan James transacted 5.6k sh — Director
2025-09-29INSIDERRITOTA JOHN transacted 5.6k sh — Director
2025-09-09INSIDERBuchan James sold 6.4k sh — Director ~$31k
2025-09-09INSIDERBuchan James sold 3.0k sh — Director ~$14k
Showing the 40 most recent of 46 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage